The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Cancer-associated Fibroblast-derived IL-6 Promotes Head and Neck Cancer Progression via the Osteopontin-NF-kappa B Signaling Pathway
Open accessAbstract
Osteopontin (OPN), a chemokine-like protein, plays a crucial role in the proliferation and metastasis of various cancers.However, how tumor stroma modulates the expression of neoplastic OPN and the multifaceted roles of OPN in head and neck cancer (HNC) are unclear.In this study, we tried to investigate the bridging role of OPN between tumor stroma and cancer cells.Methods: Immunohistochemical staining and quantitative real-time PCR were used to detect OPN expression in HNC tissues, and the correlations between OPN expression and clinicopathologic features were then analyzed.We used a co-culture assay to study the modulatory role of IL-6 on OPN expression and immunoprecipitation analysis was used to determine the endogenous interaction between OPN and integrin αvβ3.Furthermore, a xenograft assay was carried out to confirm the tumor-promoting role and the potential therapeutic value of OPN in HNC.Results: We found that OPN was significantly up-regulated in HNCs, and the elevated OPN was correlated with poor prognosis.Moreover, we identified IL-6 secreted by cancer-associated fibroblasts (CAFs) as the major upstream molecule that triggers the induction of neoplastic OPN.As such, during the interaction of fibroblasts and cancer cells, the increased neoplastic OPN induced by stromal IL-6 accelerated the growth, migration and invasion of cancer cells.More importantly, we also showed that soluble OPN could promote HNC progression via the integrin αvβ3-NF-kappa B pathway, and the combination of OPN and IL-6 had a better prognostic and diagnostic performance in HNC than either molecule alone.Conclusion: Our study identified a novel modulatory role for OPN in HNC progression and further demonstrated that the combination of OPN and IL-6 might be a promising prognostic and diagnostic indicator as well as a potential cancer therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 4×
“CAFs, the activated fibroblasts in tumor stroma, are the most abundant cells in the tumor microenvironment, play a prominent role in tumor progression and are regarded as a promising tool in cancer therapeutics [14, 53].”
BackgroundInfluentialCancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth
Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H., & Takeyama, H. (2015) · Cancers · doi:10.3390/cancers7040902 · Cited by 774
Interleukin‐6 and its receptor in cancer: Implications for Translational Therapeutics
Hong, D. S., Angelo, L. S., & Kurzrock, R. (2007) · Cancer · doi:10.1002/cncr.22999 · Cited by 370
Anderberg, C., Li, H., Fredriksson, L., Andrae, J., Betsholtz, C., Li, X., Eriksson, U., & Pietras, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2724 · Cited by 249
Ishijima, M., Rittling, S. R., Yamashita, T., Tsuji, K., Kurosawa, H., Nifuji, A., Denhardt, D. T., & Noda, M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.3.399 · Cited by 240
Cited by
CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
Zhang, H., Deng, T., Liu, R., Ning, T., Yang, H., Liu, D., Zhang, Q., Lin, D., Ge, S., Bai, M., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01168-8 · Cited by 1,016
Self-citationSignaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Qin, X., Guo, H., Wang, X., Zhu, X., Yan, M., Wang, X., Xu, Q., Shi, J., Lu, E., Chen, W., et al. (2019) · Genome Biology · doi:10.1186/s13059-018-1604-0 · Cited by 431
Self-citationMetabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming
Li, Z., Sun, C., & Qin, Z. (2021) · Theranostics · doi:10.7150/thno.62378 · Cited by 390
Self-citationCancer associated-fibroblast-derived exosomes in cancer progression
Li, C., Teixeira, A. F., Zhu, H.-J., & ten Dijke, P. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01463-y · Cited by 336
Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma
Elmusrati, A., Wang, J., & Wang, C.-Y. (2021) · International Journal of Oral Science · doi:10.1038/s41368-021-00131-7 · Cited by 312
Cancer-associated fibroblasts: overview, progress, challenges, and directions
Ping, Q., Yan, R., Cheng, X., Wang, W., Zhong, Y., Hou, Z., Shi, Y., Wang, C., & Li, R. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00318-4 · Cited by 285
Cancer-Associated Fibroblasts in Inflammation and Antitumor Immunity
Kennel, K. B., Bozlar, M., De Valk, A. F., & Greten, F. R. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1031 · Cited by 279
Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies
Mhaidly, R., & Mechta-Grigoriou, F. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101417 · Cited by 259
Mhaidly, R., & Mechta‐Grigoriou, F. (2021) · Immunological Reviews · doi:10.1111/imr.12978 · Cited by 231
Osteopontin in Cancer: Mechanisms and Therapeutic Targets
Kariya, Y., & Kariya, Y. (2022) · International Journal of Translational Medicine · doi:10.3390/ijtm2030033 · Cited by 14
Metadata
- Authors
- Qin, X., Yan, M., Wang, X., Xu, Q., Wang, X., Zhu, X., Shi, J., Li, Z., Zhang, J., & Chen, W.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2018
- Volume
- 8
- Issue
- 4
- Pages
- 921-940
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2783917155
- Cited by
- 172
- References
- 7
- FWCI
- 12.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.